Parallax Volatility Advisers’s Mirati Therapeutics, Inc. Common Stock MRTX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q1 | – | Sell |
-10,800
| Closed | -$635K | – | 2508 |
|
|
2023
Q4 | $635K | Hold |
10,800
| – | – | ﹤0.01% | 1540 |
|
|
2023
Q3 | $470K | Buy |
+10,800
| New | +$386K | ﹤0.01% | 1626 |
|
|
2023
Q1 | – | Sell |
-69,700
| Closed | -$3.16M | – | 3310 |
|
|
2022
Q4 | $3.16M | Buy |
69,700
+52,600
| +308% | +$3.4M | ﹤0.01% | 1222 |
|
|
2022
Q3 | $1.2M | Buy |
+17,100
| New | +$1.27M | ﹤0.01% | 1665 |
|
|
2022
Q1 | – | Sell |
-87,900
| Closed | -$12.9M | – | 3332 |
|
|
2021
Q4 | $12.9M | Buy |
87,900
+65,000
| +284% | +$10.1M | 0.02% | 528 |
|
|
2021
Q3 | $4.05M | Buy |
+22,900
| New | +$3.68M | ﹤0.01% | 893 |
|
|
2021
Q1 | – | Sell |
-80,000
| Closed | -$17.6M | – | 2235 |
|
|
2020
Q4 | $17.6M | Buy |
+80,000
| New | +$17.3M | 0.02% | 562 |
|
|
2020
Q2 | – | Sell |
-100
| Closed | -$8K | – | 2942 |
|
|
2020
Q1 | $8K | Sell |
100
-2,200
| -96% | -$197K | ﹤0.01% | 2367 |
|
|
2019
Q4 | $297K | Buy |
+2,300
| New | +$222K | ﹤0.01% | 1907 |
|
|
2019
Q3 | – | Sell |
-77,500
| Closed | -$7.98M | – | 3706 |
|
|
2019
Q2 | $7.98M | Buy |
+77,500
| New | +$6.03M | 0.01% | 584 |
|
|
2018
Q4 | – | Sell |
-25,000
| Closed | -$1.18M | – | 4188 |
|
|
2018
Q3 | $1.18M | Sell |
25,000
-22,500
| -47% | -$1.25M | ﹤0.01% | 1209 |
|
|
2018
Q2 | $2.34M | Buy |
+47,500
| New | +$1.79M | ﹤0.01% | 846 |
|
Other funds holding MRTX
Parallax Volatility Advisers's MRTX Position: Q3 2023 in Review
Parallax Volatility Advisers sold out of Mirati Therapeutics, Inc. Common Stock (MRTX) in Q3 2023, closing a stake of 51,988 shares — an estimated $1.86M sold.
Parallax Volatility Advisers first reported a position in MRTX in Q2 2017 and held it in 13 quarters. The position peaked at $12M in Q2 2019. 213 funds tracked by Wall St. Rank hold MRTX as of Q3 2023.
- Parallax Volatility Advisers reported no remaining Mirati Therapeutics, Inc. Common Stock position as of Q3 2023 after selling out during the quarter.
- Parallax Volatility Advisers sold 51,988 Mirati Therapeutics, Inc. Common Stock shares in Q3 2023, an estimated $1.86M.
- Parallax Volatility Advisers first reported a position in Mirati Therapeutics, Inc. Common Stock in Q2 2017 and held it in 13 quarters.
- Parallax Volatility Advisers's Mirati Therapeutics, Inc. Common Stock position peaked at $12M in Q2 2019.
- 213 funds tracked by Wall St. Rank held Mirati Therapeutics, Inc. Common Stock as of Q3 2023.
Based on Parallax Volatility Advisers's 13F filing for Q3 2023, filed 14 Nov 2023.